Search details
1.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 436, 2024 Apr 08.
Article
in English
| MEDLINE | ID: mdl-38589856
2.
Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?
Ann Hepatol
; 19(4): 380-387, 2020.
Article
in English
| MEDLINE | ID: mdl-32451205
3.
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 563, 2024 May 06.
Article
in English
| MEDLINE | ID: mdl-38711003
4.
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis.
Surgery
; 174(3): 447-456, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37357095
5.
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE2 Study.
Target Oncol
; 15(6): 801-802, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-33170485
6.
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
Tumori
; 104(6): 476-479, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-29739298
Results
1 -
6
de 6
1
Next >
>>